DMed Biopharma raises $50 mln
DMed Biopharmaceutical Co said it raised roughly $50 million in a Series B funding round led by Vivo Capital. Participating in the round were Legend Capital, Qiming Venture Partners and Lilly Asia Ventures. DMed is a clinical contract research organization that provides industry solutions to pharmaceutical and medical device companies in China and across the globe.
16 October 2019•4 mins read
